Recorded: October 2024

Antibody-drug Conjugates (ADCs) combine the targeting capabilities of antibodies with the potent cytotoxic effects of small molecule drugs. This dual nature necessitates specific strategies for ADC discovery and ADC development, paving the way for accelerated clinical development.

This webinar discussed:

  • DMPK considerations during discovery and early development
  • Bioanalytical strategies to measure ADCs
  • Immunogenicity considerations
  • PK/PD modeling and simulations

Fill the form below to access the on demand webinar: